MONROVIA, Calif., July 12, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that the first patient has been dosed in XmAb20717-01 (DUET-2), a Phase 1, first-in-human, clinical trial of XmAb®20717, a bispecific antibody that simultaneously targets PD-1 and CTLA-4 immune checkpoints for the treatment of multiple advanced solid tumors. `Built on the scaffold of Xencor`s XmAb® bispecific Fc domain, XmAb20717 is the most advanced candidate in our suite of tumor microenvironment activators,` said Paul Foster,...
|